UB Paderborn / Katalog / Suche / in CDI

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

Leukemia & lymphoma, 2015-05, Vol.56 (5), p.1252-1260

2015

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3279-3287

2013

Link zum Volltext

Verfügbarkeit prüfen

Adsorption Capacities of Ammonia‐Activated Carbon Pairs in a Single‐Bed Adsorption Cooling System

Chemical engineering & technology, 2023-04, Vol.46 (4), p.663-669

2023

Link zum Volltext

Verfügbarkeit prüfen

Pericardial effusion and cardiac tamponade following percutaneously inserted central line insertion in an extremely low-birth-weight baby: Case report and successful management

Indian journal of critical care medicine, 2017-01, Vol.21 (1), p.57-59

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Antenatal Magnesium Sulfate for Neuroprotection in Extreme Prematurity: A Comparative Observational Study

Journal of obstetrics and gynaecology of India, 2022-08, Vol.72 (Suppl 1), p.36-47

2022

Link zum Volltext

Verfügbarkeit prüfen

S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB‐B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML

HemaSphere, 2023-08, Vol.7 (S3), p.e2941723-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparison of circular- and cross-oriented phase-changing material spherical balls for charging and discharging cycles

International journal of ambient energy, 2022-12, Vol.43 (1), p.5948-5970

2022

Link zum Volltext

Verfügbarkeit prüfen

Performance of phase changing material in an artificially created cold region to promote latent heat thermal energy storage

Journal of thermal engineering, 2021-11, Vol.7 (7), p.1694-1703

2021

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Real‐World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

The oncologist (Dayton, Ohio), 2016-11, Vol.21 (11), p.1355-1361

2016

Link zum Volltext

Verfügbarkeit prüfen

Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19030-e19030

2023

Link zum Volltext

Verfügbarkeit prüfen

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Blood, 2022-11, Vol.140 (Supplement 1), p.3336-3337

2022

Link zum Volltext

Verfügbarkeit prüfen

Experimental study of single bed prototype adsorption refrigeration unit using waste heat energy

Materials today : proceedings, 2022, Vol.49, p.1799-1803

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2003-09, Vol.9 (11), p.4108-4115

2003

Link zum Volltext

Verfügbarkeit prüfen

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.10341-10342

2022

Link zum Volltext

Verfügbarkeit prüfen

Economic burden of brain metastases in patients with anaplastic lymphoma kinase positive (ALK+) non–small cell lung cancer (NSCLC) receiving second-line ALK inhibitors

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.13-13

2018

Link zum Volltext

Verfügbarkeit prüfen

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Blood, 2022-11, Vol.140 (Supplement 1), p.157-158

2022

Link zum Volltext

Verfügbarkeit prüfen

Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research

Blood, 2015-12, Vol.126 (23), p.4523-4523

2015

Link zum Volltext

Verfügbarkeit prüfen

AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S311-S311

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S168-S168

2023

Link zum Volltext

Verfügbarkeit prüfen

Photophysical behavior of a new cholesterol attached coumarin derivative and fluorescence spectroscopic studies on its interaction with bile salt systems and lipid bilayer membranes

Physical chemistry chemical physics : PCCP, 2014-01, Vol.16 (3), p.1247-1256

2014

Link zum Volltext

Verfügbarkeit prüfen

Interlocking obfuscation for anti-tamper hardware

Proceedings of the Eighth Annual Cyber Security and Information Intelligence Research Workshop, 2013, p.1-4

2013

Link zum Volltext

Verfügbarkeit prüfen

Second or none: Many patients treated for refractory differentiated thyroid cancer with small molecular kinase inhibitors do not receive a second line of therapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e17589-e17589

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood, 2021-11, Vol.138 (Supplement 1), p.1791-1791

2021

Link zum Volltext

Verfügbarkeit prüfen

Low-Dose Targeted Radioimmunotherapy (Iomab-ACT) Achieves Lymphocyte and Monocyte Depletion Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed of Refractory B-Cell ALL or DLBCL with Minimal CRS and Icans

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S167-S167

2024

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

Adsorption Capacities of Ammonia‐Activated Carbon Pairs in a Single‐Bed Adsorption Cooling System

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

Pericardial effusion and cardiac tamponade following percutaneously inserted central line insertion in an extremely low-birth-weight baby: Case report and successful management

Efficacy of Antenatal Magnesium Sulfate for Neuroprotection in Extreme Prematurity: A Comparative Observational Study

S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB‐B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML

Comparison of circular- and cross-oriented phase-changing material spherical balls for charging and discharging cycles

Performance of phase changing material in an artificially created cold region to promote latent heat thermal energy storage

Analysis of Real‐World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Experimental study of single bed prototype adsorption refrigeration unit using waste heat energy

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Economic burden of brain metastases in patients with anaplastic lymphoma kinase positive (ALK+) non–small cell lung cancer (NSCLC) receiving second-line ALK inhibitors

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research

AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

POSTER: AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

Photophysical behavior of a new cholesterol attached coumarin derivative and fluorescence spectroscopic studies on its interaction with bile salt systems and lipid bilayer membranes

Interlocking obfuscation for anti-tamper hardware

Second or none: Many patients treated for refractory differentiated thyroid cancer with small molecular kinase inhibitors do not receive a second line of therapy

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Low-Dose Targeted Radioimmunotherapy (Iomab-ACT) Achieves Lymphocyte and Monocyte Depletion Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed of Refractory B-Cell ALL or DLBCL with Minimal CRS and Icans

Suchergebnisse filtern